Similar articles

• Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

  Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ. Matchaba P, et al. Clin Ther. 2005 Aug;27(8):1196-214. doi: 10.1016/j.clinthera.2005.07.019. Clin Ther. 2005. PMID: 16199245 Review.
• Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.

  Hawkey CJ, Gitton X, Hoexter G, Richard D, Weinstein WM. Hawkey CJ, et al. Clin Gastroenterol Hepatol. 2006 Jan;4(1):57-66. doi: 10.1016/s1542-3565(05)00976-6. Clin Gastroenterol Hepatol. 2006. PMID: 16431306
• Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.

  Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Kivitz AJ, et al. Aliment Pharmacol Ther. 2004 Jun 1;19(11):1189-98. doi: 10.1111/j.1365-2036.2004.01956.x. Aliment Pharmacol Ther. 2004. PMID: 15153172 Clinical Trial.
• Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.

  Bannwarth B, Berenbaum F. Bannwarth B, et al. Expert Opin Investig Drugs. 2005 Apr;14(4):521-33. doi: 10.1517/13543784.14.4.521. Expert Opin Investig Drugs. 2005. PMID: 15882125 Review.
• Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.

  Hawkey CJ, Weinstein WM, Smalley W, Gitton X, Sallstig P, Stricker K, Krammer G, Mellein B, Richard D, Matchaba P. Hawkey CJ, et al. Gastroenterology. 2007 Jul;133(1):57-64. doi: 10.1053/j.gastro.2007.04.045. Epub 2007 Apr 27. Gastroenterology. 2007. PMID: 17631131 Clinical Trial.